![thumbnail image](https://user-images.strikinglycdn.com/res/hrscywv4p/image/upload/c_fill,g_faces:center,h_300,q_90,w_300/xolcz88i3w4ojymlwoh3.png)
![broken image](https://user-images.strikinglycdn.com/res/hrscywv4p/image/upload/c_limit,h_540,w_720/inz2jych8gvd0rs5e00t.jpg)
SAVING LIVES NOW
ONE CANCER PATIENT
AT THE TIME
Our OneRNA® platform enables repurposing of approved drugs on an individual patient basis and rapid development of novel RNA Therapeutics
ARE YOU A DOCTOR OR A PATIENT ?
Looking for better treatment options for your patients? Our OneRNA® Platform enables repurposing approved drugs on an individual patient basis
ARE YOU DEVELOPING CURES?
Using just one biomarker can save $1B during clinical development.
The OneRNA Platform makes the companion diagnostic into an algorithm and rapidly translates RNA code to novel RNA Theraputics
INVEST IN US
HELP US LAUNCH OneRNA® in WOMENS CANCERS
We are raising $1M+ in parallel with a Series A to
launch OneRNA® in Breast and Ovarian Cancer.
After our series A we can expand into other cancers.
The OneRNA® Platform
By analyzing RNA we can monitor health, detect disease, and design next-generation cures
What is the difference between RNA and DNA?
RNA is the software of the cell and can inform us of the actual presence of disease, whereas DNA is the hardware and mainly informs us of the risk of disease. DNA panels used in cancer tissue analyses up to 500 genes typically only identify one drug in up to 40% of the cases.
We don't like guessing, and therefore we analyze ALL the +20,000 mRNA’s in the sample. This makes our OneRNA® platform the most powerful platform in the industry and it enables the implementation of AI into standard of care. They was y we built it is tissue and disease agnostic and exponentially scalable.
RNA is coding for proteins and proteins are targets for drugs. Today RNA is directly a target for drugs and a drug itself.
We are pioneers in analyzing RNA using sequencing and our OneRNA® test has been validated in breast and ovarian cancer and identifies multiple treatment options and/or clinical studies for practically all patients.
We are now developing methods to rapidly translate RNA Code to RNA Therapeutics to further individualize treatment.
When making treatment decisions, knowledge is power.
A cancer diagnosis is life-changing. Ask your doctor about the testing options, including our OneRNA® test in breast and ovarian cancer. OneRNA® analyses all mRNA in your tumor’s tissue, which may help individualize a treatment plan. Because no drugs are effective in all patients, it's essential to have a plan for the next steps.
WHO WE ARE
Experienced Management Team with Startup RNA
Gitte Pedersen
CEO and co-founder
Gitte Pedersen, CEO is a former executive at Novo Nordisk. She has advised the Danish Government and early-stage biotech companies regarding their corporate development in the US
Follow at Linkedin
WHO'S TALKING ABOUT US
We have been featured in Forbes twice, GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Harvard Business Angels, Investor Circle, Pipeline Angels, and a family office; Centurion Holding in New York.
We are a Springboard alum company and among the 500 women-owned technology companies they have supported. Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Technology Challenge, and was invited to dinner with Branson on Necker’s Island.
We have brought the company from idea to commercialization for grants, revenue, and angel funding, and are now implementing capabilities to rapidly translate RNA code to novel RNA Theraputics in collaborations with Biotech and Pharma
This is our founder story:
Articles, Grants, Investors and Customers
These are our supporters, funders and customers
In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.
WANT TO LEARN MORE ?
DISCLAIMER The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.
@2024